AbbVie's Juvmo Adds 1.7 Hours of Dyskinesia-Free Time in Parkinson's Trial
ABBV sits 38% above its 52-week low of $190.75.
Summary
AbbVie's Juvmo (tavapadon) plus levodopa delivered 1.7 extra hours per day of controlled, dyskinesia-free time versus 0.6 hours for placebo in the TEMPO-3 trial. This is the first detailed efficacy data for Juvmo in Parkinson's disease since its FDA approval on September 28. The company also announced a partnership with Valkai AI to integrate AI tools into clinical R&D, aiming to speed insight generation and shorten development timelines. The AI collaboration is a modest strategic move, but the Juvmo data strengthens the commercial case for a recently approved drug in a large market. Watch for full TEMPO-3 results presentation and any updates on Juvmo launch timing.
At the time of this announcement, ABBV was trading at $263.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $465.3B. The 52-week trading range was $190.75 to $269.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.